LEVOSIMENDAN AS BRIDGING THERAPY IN ADVANCED HEART FAILURE: CURRENT STATE OF KNOWLEDGE AND CLINICAL PERSPECTIVES
Abstract
Advanced heart failure (AHF) constitutes a terminal expression of cardiovascular disease, associated with severe, refractory symptoms and high mortality despite optimized medical therapy. Levosimendan, a first-in-class inodilator, addresses this challenge, acting as a calcium sensitizer and potassium channel opener. Its unique tripartite mechanism provides positive inotropy independently of the cAMP pathway, critically avoiding increased intracellular calcium or myocardial oxygen demand. The active metabolite, OR-1896, ensures prolonged hemodynamic benefits lasting up to two weeks, supporting intermittent, outpatient bridging strategies. This systematic literature review synthesized current evidence by applying a rigorous search strategy across biomedical databases, resulting in the inclusion of 32 scientific publications encompassing high-level evidence such as meta-analyses, randomized controlled trials (RCTs), and cohort studies. Pooled analyses suggest that repetitive levosimendan administration significantly improves Left Ventricular Ejection Fraction (LVEF), reduces NT-proBNP levels, and is associated with a reduced risk of all-cause mortality (RR 0.60). Furthermore, it confers vital organoprotective effects, notably improving renal function in patients awaiting heart transplantation (HTx), and its preoperative use as a "bridge to transplant" (BTT) is deemed safe. Despite compelling data from small RCTs (e.g., LION-HEART), the field requires larger, definitive studies—such as the ongoing LEIA-HF trial—to establish the precise role of levosimendan in contemporary AHF management.
References
Abbate, A., & Van Tassell, B. W. (2018). Levosimendan in Advanced Heart Failure: Where Do We Stand?. Journal of cardiovascular pharmacology, 71(3), 127–128. https://doi.org/10.1097/FJC.0000000000000539
Altenberger, J., Gustafsson, F., Harjola, V. P., Karason, K., Kindgen-Milles, D., Kivikko, M., Malfatto, G., Papp, Z., Parissis, J., Pollesello, P., Pölzl, G., & Tschöpe, C. (2018). Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications. Journal of cardiovascular pharmacology, 71(3), 129–136. https://doi.org/10.1097/FJC.0000000000000533
Apostolo, A., Vignati, C., Della Rocca, M., De Martino, F., Berna, G., Campodonico, J., Contini, M., Muratori, M., Palermo, P., Mapelli, M., Alimento, M., Pezzuto, B., & Agostoni, P. (2022). Why Levosimendan Improves the Clinical Condition of Patients With Advanced Heart Failure: A Holistic Approach. Journal of cardiac failure, 28(3), 509–514. https://doi.org/10.1016/j.cardfail.2021.10.009
Bouchez, S., Fedele, F., Giannakoulas, G., Gustafsson, F., Harjola, V. P., Karason, K., Kivikko, M., von Lewinski, D., Oliva, F., Papp, Z., Parissis, J., Pollesello, P., Pölzl, G., & Tschöpe, C. (2018). Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application. Cardiovascular drugs and therapy, 32(6), 617–624. https://doi.org/10.1007/s10557-018-6838-2
Codina, P., Dobarro, D., de Juan-Bagudá, J., De Frutos, F., Lupón, J., Bayes-Genis, A., Gonzalez-Costello, J., & Spanish LEVO‐D registry Collaborators (2023). Heart failure risk scores in advanced heart failure patients: insights from the LEVO-D registry. ESC heart failure, 10(5), 2875–2881. https://doi.org/10.1002/ehf2.14400
Comín-Colet, J., Manito, N., Segovia-Cubero, J., Delgado, J., García Pinilla, J. M., Almenar, L., Crespo-Leiro, M. G., Sionis, A., Blasco, T., Pascual-Figal, D., Gonzalez-Vilchez, F., Lambert-Rodríguez, J. L., Grau, M., Bruguera, J., & LION-HEART Study Investigators (2018). Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. European journal of heart failure, 20(7), 1128–1136. https://doi.org/10.1002/ejhf.1145
Dobarro, D., Donoso-Trenado, V., Solé-González, E., Moliner-Abós, C., Garcia-Pinilla, J. M., Lopez-Fernandez, S., Ruiz-Bustillo, S., Diez-Lopez, C., Castrodeza, J., Méndez-Fernández, A. B., Vaqueriza-Cubillo, D., Cobo-Marcos, M., Tobar, J., Sagasti-Aboitiz, I., Rodriguez, M., Escolar, V., Abecia, A., Codina, P., Gómez-Otero, I., Pastor, F., … Gonzalez-Costello, J. (2023). Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry. ESC heart failure, 10(2), 1193–1204. https://doi.org/10.1002/ehf2.14278
Elsaeidy, A. S., Abuelazm, M., Ghaly, R., Soliman, Y., Amin, A. M., El-Gohary, M., Elshenawy, S., Seri, A. R., Abdelazeem, B., Patel, B., & Bianco, C. (2024). The Efficacy and Safety of Levosimendan in Patients with Advanced Heart Failure: An Updated Meta-Analysis of Randomized Controlled Trials. American journal of cardiovascular drugs : drugs, devices, and other interventions, 24(6), 775–790. https://doi.org/10.1007/s40256-024-00675-z
Ferreira Reis, J., Valentim Gonçalves, A., Ilhão Moreira, R., Pereira da Silva, T., Timóteo, A. T., Pombo, D., Carvalho, T., Correia, C., Santos, C., & Cruz Ferreira, R. (2023). Levosimendan in outpatients with advanced heart failure: Single-center experience of 200 intermittent perfusions. Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 42(4), 335–343. https://doi.org/10.1016/j.repc.2022.03.006
García-González, M. J., Aldea Perona, A., Lara Padron, A., Morales Rull, J. L., Martínez-Sellés, M., de Mora Martin, M., López Díaz, J., López Fernandez, S., Ortiz Oficialdegui, P., & Jiménez Sosa, A. (2021). Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study. ESC heart failure, 8(6), 4820–4831. https://doi.org/10.1002/ehf2.13670
Giannini, C., Petronio, A. S., Fiorelli, F., Liga, R., Spontoni, P., De Carlo, M., Marraccini, E., Pieroni, A., & Guarracino, F. (2017). Effects of levosimendan in patients with severe functional mitral regurgitation undergoing MitraClip implantation. Journal of cardiovascular medicine (Hagerstown, Md.), 18(9), 679–686. https://doi.org/10.2459/JCM.0000000000000537
Guzman-Bofarull, J., Martín-Centellas, A., Couto-Mallon, D., Borràs, R., Arenas-Loriente, A., Rivas-Lasarte, M., Segovia-Cubero, J., Crespo-Leiro, M. G., García-Álvarez, A., & Farrero, M. (2025). Impact of Pre-Heart Transplant Levosimendan Administration on Post-Transplant Vasoplegia and Primary Graft Dysfunction. Clinical transplantation, 39(10), e70327. https://doi.org/10.1111/ctr.70327
Książczyk, M., Gruchała, M., Stopczyńska, I., & Lelonek, M. (2023). A favorable alliance between repetitive use of levosimendan and advanced heart failure: Polish two-centered inpatient perspective in need of validation. Kardiologia polska, 81(3), 287–289. https://doi.org/10.33963/KP.a2023.0034
Lannemyr, L., Ricksten, S. E., Rundqvist, B., Andersson, B., Bartfay, S. E., Ljungman, C., Dahlberg, P., Bergh, N., Hjalmarsson, C., Gilljam, T., Bollano, E., & Karason, K. (2018). Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment:A Randomized Double-Blind Controlled Trial. Journal of the American Heart Association, 7(16), e008455. https://doi.org/10.1161/JAHA.117.008455
Lelonek, M., Stopczyńska, I., Korościk, E., Straburzyńska-Migaj, E., & Gruchała, M. (2020). Multicenter experiences with levosimendan therapy and its safety in patients with decompensated advanced heart failure. Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 29(11), 1305–1312. https://doi.org/10.17219/acem/126301
Milwidsky, A., Frydman, S., Laufer-Perl, M., Sadeh, B., Sapir, O., Granot, Y., Hochstadt, A., Korotetski, L., Ketchker, L., Topilsky, Y., Banai, S., & Havakuk, O. (2022). Intermittent inotropic therapy with levosimendan vs. milrinone in advanced heart failure patients. ESC heart failure, 9(2), 1487–1491. https://doi.org/10.1002/ehf2.13807
Najjar, E., Stålhberg, M., Hage, C., Ottenblad, E., Manouras, A., Haugen Löfman, I., & Lund, L. H. (2018). Haemodynamic effects of levosimendan in advanced but stable chronic heart failure. ESC heart failure, 5(3), 302–308. https://doi.org/10.1002/ehf2.12272
Papp, Z., Agostoni, P., Alvarez, J., Bettex, D., Bouchez, S., Brito, D., Černý, V., Comin-Colet, J., Crespo-Leiro, M. G., Delgado, J. F., Édes, I., Eremenko, A. A., Farmakis, D., Fedele, F., Fonseca, C., Fruhwald, S., Girardis, M., Guarracino, F., Harjola, V. P., Heringlake, M., … Pollesello, P. (2020). Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. Journal of cardiovascular pharmacology, 76(1), 4–22. https://doi.org/10.1097/FJC.0000000000000859
Pölzl, G., Allipour Birgani, S., Comín-Colet, J., Delgado, J. F., Fedele, F., García-Gonzáles, M. J., Gustafsson, F., Masip, J., Papp, Z., Störk, S., Ulmer, H., Vrtovec, B., Wikström, G., & Altenberger, J. (2019). Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period. ESC heart failure, 6(1), 174–181. https://doi.org/10.1002/ehf2.12366
Pölzl, G., Altenberger, J., Baholli, L., Beltrán, P., Borbély, A., Comin-Colet, J., Delgado, J. F., Fedele, F., Fontana, A., Fruhwald, F., Giamouzis, G., Giannakoulas, G., Garcia-González, M. J., Gustafsson, F., Kaikkonen, K., Kivikko, M., Kubica, J., von Lewinski, D., Löfman, I., Malfatto, G., … Pollesello, P. (2017). Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. International journal of cardiology, 243, 389–395. https://doi.org/10.1016/j.ijcard.2017.05.081
Pölzl, G., Altenberger, J., Comín-Colet, J., Delgado, J. F., Fedele, F., García-González, M. J., Gustafsson, F., Masip, J., Papp, Z., Störk, S., Ulmer, H., Maier, S., Vrtovec, B., Wikström, G., Zima, E., Bauer, A., & LeoDOR Investigators (2023). Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period: The multinational randomized LeoDOR trial. European journal of heart failure, 25(11), 2007–2017. https://doi.org/10.1002/ejhf.3006
Ponz de Antonio, I., de Juan Bagudá, J. S., Rodríguez Chaverri, A., García-Cosío Carmena, M. D., Arribas Ynsaurriaga, F., & Delgado Jiménez, J. F. (2020). Levosimendan as bridge to transplant in patients with advanced heart failure. Revista espanola de cardiologia (English ed.), 73(5), 422–424. https://doi.org/10.1016/j.rec.2019.10.026
Ráduly, A. P., Tóth, A., Sárkány, F., Horváth, B., Szentandrássy, N., Nánási, P. P., Csanádi, Z., Édes, I., Papp, Z., & Borbély, A. (2023). Omecamtiv mecarbil augments cardiomyocyte contractile activity both at resting and systolic Ca2+ levels. ESC heart failure, 10(2), 1326–1335. https://doi.org/10.1002/ehf2.14300
Silvetti, S., & Nieminen, M. S. (2016). Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis. International journal of cardiology, 202, 138–143. https://doi.org/10.1016/j.ijcard.2015.08.188
Silvetti, S., Belletti, A., Fontana, A., & Pollesello, P. (2017). Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials. ESC heart failure, 4(4), 595–604. https://doi.org/10.1002/ehf2.12177
Silvetti, S., Pollesello, P., & Belletti, A. (2024). Repeated Levosimendan Infusions in the Management of Advanced Heart Failure: Review of the Evidence and Meta-analysis of the Effect on Mortality. Journal of cardiovascular pharmacology, 83(2), 144–157. https://doi.org/10.1097/FJC.0000000000001506
Sumanaru, D., Josseran, L., Essid, A., Mbieleu, B., Haegy, I., & Bergounioux, J. (2019). Levosimendan as Rescue Therapy for Acute Heart Failure in a Patient with Duchenne Muscular Dystrophy. Pediatric cardiology, 40(3), 668–670. https://doi.org/10.1007/s00246-019-02072-9
Teixeira, A. R., Barbas de Albuquerque, F., Pereira-da-Silva, T., Gonçalves, A. V., Ilhão Moreira, R., Timóteo, A. T., Alves, J., Barquinha, S., Mata, R., Dias, M., Cacela, D., & Cruz Ferreira, R. (2025). Hemodynamic effect of outpatient levosimendan infusion assessed daily using the CardioMEMS™ invasive remote monitoring system. Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 44(5), 281–288. https://doi.org/10.1016/j.repc.2024.11.014
Tycińska, A., Gierlotka, M., Bartuś, S., Gąsior, M., Główczyńska, R., Grześk, G., Jaguszewski, M., Kasprzak, J. D., Kubica, J., Legutko, J., Leszek, P., Nessler, J., Pacileo, G., Ponikowski, P., Sobkowicz, B., Stępińska, J., Straburzyńska-Migaj, E., Wojakowski, W., Zawiślak, B., Zymliński, R., … LEIA-HF Investigators (2022). Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design. Advances in medical sciences, 67(1), 18–22. https://doi.org/10.1016/j.advms.2021.10.001
Visco, V., Esposito, C., Rispoli, A., Di Pietro, P., Izzo, C., Loria, F., Di Napoli, D., Virtuoso, N., Bramanti, A., Manzo, M., Vecchione, C., & Ciccarelli, M. (2024). The favourable alliance between CardioMEMS and levosimendan in patients with advanced heart failure. ESC heart failure, 11(5), 2835–2848. https://doi.org/10.1002/ehf2.14838
von Scheidt, W., Pauschinger, M., & Ertl, G. (2016). Long-term intravenous inotropes in low-output terminal heart failure?. Clinical research in cardiology : official journal of the German Cardiac Society, 105(6), 471–481. https://doi.org/10.1007/s00392-016-0968-y
Zheng, Q., Lan, H., Guo, Q., Li, C., Xiong, T., Zhang, J., Wang, G., Dong, N., & Shi, J. (2023). Preoperative Levosimendan Administration in Heart Transplant Patients with Severe Hepatic and Renal Impairment: A Retrospective Study. The heart surgery forum, 26(4), E346–E357. https://doi.org/10.59958/hsf.5433
Copyright (c) 2025 Marcin Schulz, Michał Kulczak, Dawid Studziński, Anna Kołcz, Agnieszka Morawa, Karolina Osińska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
